ライフサイエンスコーパス: glycogen synthase

1 ugh a remarkable adaptation of the bacterial glycogen synthase.

2 t, confirming the inhibitory role of Fgk3 on glycogen synthase.

3 ciated glycogen and with stable knockdown of glycogen synthase 1, which inhibited (18)F-NFTG uptake,

4 Constitutive reduction of glycogen synthase-1 (GYS1) activity prevents murine LD,

5 ulation of glucose transporter 2 (GLUT2) and glycogen synthase 2 (GYS2); while expression of gluconeo

6 ence of interleukin-7 (IL-7), IL-21, and the glycogen synthase-3beta inhibitor TWS119, and geneticall

7 Furthermore, glycogen synthase activity and glycogen accumulation wer

8 ates insulin and catecholamine signaling and glycogen synthase activity in skeletal muscle.

9 sensitivity was not associated with enhanced glycogen synthase activity or proximal insulin signaling

10 cogen content was approximately 50% greater, glycogen synthase activity was approximately 50% greater

11 Insulin-stimulated glycogen synthase activity was completely ablated during

12 rylation of TBC1D4 Ser(318) and Ser(704) and glycogen synthase activity were greater in the exercised

13 wer starting glycogen content, and increased glycogen synthase activity, together with increased musc

14 or cell cycle transit as well as controlling glycogen synthase activity.

15 Akt2 activation, which specifically inhibits glycogen synthase activity.

16 inhibition of glucose-6-phosphate-stimulated glycogen synthase activity.

17 e and phosphorylation of inhibiting sites on glycogen synthase all increased.

18 ogen shunt implicates the high activities of glycogen synthase and fructose bisphosphatase in tumors

19 Firstly, the periportal zonation of both glycogen synthase and the oxidative phosphorylation enzy

20 ing also increased the insulin activation of glycogen synthase by 60%, GLUT4 expression by 16%, and 5

21 levels of oxidants or genetic inhibition of glycogen synthase depletes glycogen stores and extends t

22 Moreover, glycogen synthase expression was greatly enhanced, consi

23 the Gys2 gene encoding the liver isoform of glycogen synthase generates a mouse strain (LGSKO) that

24 ABA increases expression of important glycogen synthase, glucose, fatty acid and mitochondrial

25 Three homologous candidate genes, glycogen synthase (glys), atp-binding cassette transport

26 e widely conserved in plant SS and bacterial glycogen synthase (GS) isoforms.

27 om glucose through the cooperative action of glycogen synthase (GS), glycogenin (GN), and glycogen br

28 bitors of the key glycogen synthetic enzyme, glycogen synthase (GS), we identified a substituted imid

29 phosphorylated glycogen phosphorylase (GPa), glycogen synthase (GSa) - respectively activated and ina

30 c process, in Neurospora crassa We find that glycogen synthase (gsn) mRNA, glycogen phosphorylase (gp

31 granules and the glycogen conversion enzymes glycogen synthase I and glycogen phosphorylase BB, dispe

32 They activate glycogen synthase in insulin receptor-expressing CHO-IR

33 lecular signaling at the level of TBC1D4 and glycogen synthase in muscle.

34 PKB/Akt in turn inactivates glycogen synthase kinase (GSK) 3, a major regulator of m

35 Studies have implicated signaling through glycogen synthase kinase (GSK) 3alpha/beta in the activa

36 work, we demonstrate that overexpression of glycogen synthase kinase (GSK) 3beta in neural precursor

37 Glycogen synthase kinase (GSK)-3 is a ubiquitously expre

38 The enzymes 5-lipoxygenase (5-LO) and glycogen synthase kinase (GSK)-3 represent promising dru

39 Blast TBI increased glycogen synthase kinase (GSK)-3beta activities in ApoE4

40 These same stimuli enhance glycogen synthase kinase (GSK)-3beta activity through in

41 Glycogen synthase kinase (GSK)-3beta phosphorylates the

42 Here, we provide evidence that glycogen synthase kinase (GSK)-3beta promotes cell proli

43 rved that phosphorylation of Gpa2 depends on glycogen synthase kinase (GSK).

44 show that the dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, VP3.15, a het

45 Mechanistically, Tanshinone IIA blunted glycogen synthase kinase (GSK)3beta overactivity and hyp

46 used to deliver low doses of small molecule glycogen synthase kinase (GSK-3) antagonists that promot

47 exerted its positive effect by inhibition of glycogen synthase kinase (GSK3) activity and enhancement

48 contrast, phosphomimetic substitution of the glycogen synthase kinase (GSK3beta) site in the Pro/Ala-

49 Here we show that glycogen synthase kinase 3 (GSK-3) interacts with and ph

50 a-catenin pathway through phosphorylation of glycogen synthase kinase 3 (GSK-3), suggesting that this

51 racellular signal-regulated kinase (ERK) and glycogen synthase kinase 3 (GSK-3).

52 Glycogen synthase kinase 3 (GSK-3, isoforms alpha and be

53 but REDD1-mediated Nrf2 degradation required glycogen synthase kinase 3 (GSK3) activity and Ser-351/S

54 Glycogen synthase kinase 3 (GSK3) alpha and beta are 2 h

55 maller receptor-mediated vesicles containing glycogen synthase kinase 3 (GSK3) and protein arginine e

56 We show that glycogen synthase kinase 3 (GSK3) and protein arginine m

57 ion in p-AKT (S473), which in turn activated glycogen synthase kinase 3 (GSK3) and reduced beta-caten

58 cells due to its constant phosphorylation by glycogen synthase kinase 3 (GSK3) and subsequent proteas

59 Here we show how inhibiting glycogen synthase kinase 3 (GSK3) can improve the differ

60 ition of protein kinase C-beta (PKCbeta) and glycogen synthase kinase 3 (GSK3) causes synergistic apo

61 ng approaches, we show how the activation of glycogen synthase kinase 3 (GSK3) contributes to neurona

62 rt the evolutionary importance of the enzyme Glycogen Synthase Kinase 3 (GSK3) for maintaining podocy

63 differentiation through negatively affecting glycogen synthase kinase 3 (GSK3) function.

64 Herein, we investigated the role of glycogen synthase kinase 3 (GSK3) in liver regeneration

65 in collagen I 3D cultures in the absence of glycogen synthase kinase 3 (GSK3) inhibition, hPSC-deriv

66 Glycogen synthase kinase 3 (GSK3) inhibitors were identi

67 Glycogen synthase kinase 3 (GSK3) is a genetically valid

68 Here we show that glycogen synthase kinase 3 (Gsk3) is a metabolic sensor

69 Phosphorylation of glycogen synthase kinase 3 (GSK3) isoforms alpha/beta by

70 phosphodegron (CPD) signal, a target site of glycogen synthase kinase 3 (GSK3) kinase and Fbw7 ubiqui

71 We also demonstrate that the kinase glycogen synthase kinase 3 (GSK3) mediates the FBW7-depe

72 Here, we show the expression of the Glycogen synthase kinase 3 (GSK3) MoGSK1 in M. oryzae is

73 we demonstrate a potent effect of inhibiting glycogen synthase kinase 3 (GSK3) on definitive endoderm

74 Suppression of glycogen synthase kinase 3 (GSK3) or FBXW7 rescued Mcl-1

75 Glycogen synthase kinase 3 (GSK3) plays a central role i

76 We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-beta

77 itor pools and plays a key role in mediating glycogen synthase kinase 3 (GSK3) signaling during brain

78 Here, we report that Wnt/glycogen synthase kinase 3 (GSK3) signaling functions po

79 ptor (D2R) and protein kinase B (PKB or Akt)/glycogen synthase kinase 3 (GSK3) signaling in the ventr

80 sites and secondary casein kinase 1 (CK1) or glycogen synthase kinase 3 (GSK3) sites was carefully ev

81 here show a novel mode of eIF6 regulation by glycogen synthase kinase 3 (GSK3) that is predominantly

82 Glycogen synthase kinase 3 (GSK3) was identified as an e

83 Glycogen synthase kinase 3 (GSK3), a prominent enzyme in

84 clock proteins by casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3), appear conserved amon

85 ation of proteins (Wnt/STOP), which inhibits glycogen synthase kinase 3 (GSK3)-dependent protein ubiq

86 Arabidopsis GLYCOGEN SYNTHASE KINASE 3 (GSK3)-like kinases play vari

87 mitochondrial respiratory quiescence through glycogen synthase kinase 3 (GSK3).

88 stabilizing many proteins phosphorylated by glycogen synthase kinase 3 (GSK3).

89 diated degradation due to phosphorylation by glycogen synthase kinase 3 (Gsk3).

90 al domain, priming it for phosphorylation by glycogen synthase kinase 3 (GSK3).

91 mine analogues which are inhibitors of human glycogen synthase kinase 3 (GSK3).

92 We show that this process is dependent on glycogen synthase kinase 3 (GSK3): GSK3 was associated w

93 pathways including phosphoinositide 3-kinase/glycogen synthase kinase 3 (PI3K/GSK3) signaling, with s

94 : it increases Akt phosphorylation, inhibits glycogen synthase kinase 3 activity, reduces IkappaB pho

95 hatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism o

96 atenin was required for BRB restoration, but glycogen synthase kinase 3 alpha/beta (GSK-3alpha/beta)

97 We demonstrate that inhibitors of glycogen synthase kinase 3 alpha/beta (GSK3alpha/beta) e

98 ing protein, p53, which is phosphorylated by glycogen synthase kinase 3 at serine 33 and then ubiquit

99 evealed increased phosphorylation of AKT and glycogen synthase kinase 3 beta (GSK-3beta) in both the

100 Glycogen synthase kinase 3 beta (GSK-3beta) is a central

101 through a kinome-wide screen, we found that glycogen synthase kinase 3 beta (GSK-3beta) was robustly

102 he virulence of P. gingivalis (Pg) affecting glycogen synthase kinase 3 beta (GSK-3beta)/nuclear fact

103 The BCR attenuates glycogen synthase kinase 3 beta (GSK3beta) activity to s

104 Glycogen synthase kinase 3 beta (GSK3beta) is a critical

105 Glycogen synthase kinase 3 beta (GSK3beta) is highly ina

106 We identify an interaction of BMP and Wnt/glycogen synthase kinase 3 beta (GSK3beta) pathways via

107 activator of smoothened, and phosphorylated glycogen synthase kinase 3 beta (pGSK-3B), an inactive f

108 we found that CAMK4 phosphorylates GSK3beta (glycogen synthase kinase 3 beta), activates the Wnt path

109 ibition of the pro-apoptotic molecules, JNK, glycogen synthase kinase 3 beta, or caspases, toxicity i

110 evealed a role for heat shock protein 90 and glycogen synthase kinase 3 but not casein kinase 1 nor L

111 nt which was suppressed by co-treatment with glycogen synthase kinase 3 inhibitor SB216763.

112 Our data reveal that glycogen synthase kinase 3 signaling also regulates eEF2

113 way seems to occur from Dishevelleds to axin/glycogen synthase kinase 3(GSK3)/beta-catenin complexes

114 d THC-induced downregulation of local GSK-3 (glycogen synthase kinase 3) and Akt signaling pathways d

115 cked cortical downregulation of local GSK-3 (glycogen synthase kinase 3) and Akt signaling pathways,

116 (+) NPCs with a pharmacological inhibitor of glycogen synthase kinase 3, a known regulator of WNT sig

117 in sensitivity likely through increased Akt, glycogen synthase kinase 3, and AMPK phosphorylation; an

118 an inhibitor of cyclin-dependent kinases and glycogen synthase kinase 3, as a modulator of parkin rec

119 inhibition of Janus kinase 1, inhibition of Glycogen synthase kinase 3, or addition of NRG1 signific

120 screen for anti-fibrotic compounds targeting glycogen synthase kinase 3, which has a consistent role

121 y treating SH-SY5Y cells with inhibitors for glycogen synthase kinase 3-beta (GSK3beta) and cyclin-de

122 Insulin/GSK-3beta (glycogen synthase kinase 3-beta) signalling induces cycl

123 TA accelerated beta-catenin degradation by a glycogen synthase kinase 3-beta-dependent mechanism.

124 s of the brassinosteroid (BR) signaling, the glycogen synthase kinase 3/Arabidopsis SHAGGY-like kinas

125 y phosphorylated at Thr(714) and Ser(727) by glycogen synthase kinase 3alpha and -beta (GSK-3alpha/be

126 Phosphorylation of tau at Thr212 and glycogen synthase kinase 3beta (GSK-3beta) at Ser9 was r

127 ave been some reports on MTDLs targeting the glycogen synthase kinase 3beta (GSK-3beta) enzyme, due t

128 Glycogen synthase kinase 3beta (GSK-3beta) has been sugg

129 Glycogen synthase kinase 3beta (GSK-3beta) is a primary

130 ected T cells and reduces phosphorylation of glycogen synthase kinase 3beta (GSK-3beta), a downstream

131 ion of specific Akt substrates, most notably glycogen synthase kinase 3beta (Gsk-3beta).

132 ound a residue that can be phosphorylated by glycogen synthase kinase 3beta (GSK-3beta).

133 Consequently, GRbeta-Ad mice had increased glycogen synthase kinase 3beta (GSK3beta) activity and r

134 , N-methyl-d-aspartate receptor function, or glycogen synthase kinase 3beta (GSK3beta) activity or ex

135 ver, hypoinsulinemia leads to an increase in glycogen synthase kinase 3beta (GSK3beta) activity that,

136 ssociated with insulin resistance, decreased glycogen synthase kinase 3beta (GSK3beta) activity, acti

137 (NF-kappaB) pathway and in the induction of glycogen synthase kinase 3beta (GSK3beta) activity, resu

138 of beta-catenin by enhancing binding between glycogen synthase kinase 3beta (GSK3beta) and beta-caten

139 osphorylation on p53 at Ser-33 and Ser-37 by glycogen synthase kinase 3beta (GSK3beta) and DNA-depend

140 Cellular targets of Li(+), such as glycogen synthase kinase 3beta (GSK3beta) and G proteins

141 oteasomal degradation via phosphorylation by glycogen synthase kinase 3beta (GSK3beta) and recognitio

142 ted protein kinase kinase 4 (MKK4), JNK, and glycogen synthase kinase 3beta (GSK3beta) and thereby de

143 (APC), casein kinase 1alpha (CK1alpha), and glycogen synthase kinase 3beta (GSK3beta) and undergoes

144 TGF-beta1 expression and hyperacetylation of glycogen synthase kinase 3beta (GSK3beta) at residue K15

145 tes diminished inhibitory phosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser-9 in th

146 ects against hepatic steatosis by inhibiting glycogen synthase kinase 3beta (GSK3beta) by enhancing s

147 Glycogen synthase kinase 3beta (GSK3beta) deactivation a

148 Glycogen synthase kinase 3beta (GSK3beta) has been shown

149 ppress many signaling pathways that activate glycogen synthase kinase 3beta (GSK3beta) implicated in

150 quent signaling, causing overt activation of glycogen synthase kinase 3beta (GSK3beta) in nerves of m

151 synthesis is associated with inactivation of glycogen synthase kinase 3beta (GSK3beta) in renal cells

152 A member of this family is glycogen synthase kinase 3beta (GSK3beta) interaction pr

153 We show that glycogen synthase kinase 3beta (GSK3beta) interacts with

154 Glycogen synthase kinase 3beta (GSK3beta) is a constitut

155 Inhibition of glycogen synthase kinase 3beta (GSK3beta) is a shared ac

156 g pathway involving AKT Ser/Thr kinase (AKT)/glycogen synthase kinase 3beta (GSK3beta) or paxillin.

157 of TGF-beta receptors and p38 MAPK increased glycogen synthase kinase 3beta (GSK3beta) phosphorylatio

158 In this study, we demonstrate that glycogen synthase kinase 3beta (GSK3beta) regulates ST2L

159 d by the core clock oscillator BMAL1 and AKT/glycogen synthase kinase 3beta (GSK3beta) signaling path

160 ide 3-kinase (PI3K)-AKT Ser/Thr kinase (AKT)-glycogen synthase kinase 3beta (GSK3beta) signaling path

161 [e.g., strong bias toward phosphorylation of glycogen synthase kinase 3beta (GSK3beta) via the full-l

162 peractivation and subsequent inactivation of glycogen synthase kinase 3beta (GSK3beta), a negative re

163 e IGF-I, IGF binding protein-1 (IGFBP-1) and glycogen synthase kinase 3beta (GSK3beta), as one major

164 Psychotropic medications target glycogen synthase kinase 3beta (GSK3beta), but the funct

165 ivation, which results in hyperactivation of glycogen synthase kinase 3beta (GSK3beta), followed by p

166 The phosphorylation is catalyzed by glycogen synthase kinase 3beta (GSK3beta), ultimately re

167 hic signaling intermediates, such as Akt and glycogen synthase kinase 3beta (GSK3beta), were dephosph

168 CUGBP1 activity is controlled by glycogen synthase kinase 3beta (GSK3beta), which is elev

169 dent on LFA-1/ICAM-1-induced inactivation of glycogen synthase kinase 3beta (GSK3beta), which is medi

170 the canonical regulation of beta-catenin via glycogen synthase kinase 3beta (GSK3beta)-dependent degr

171 PI exposure abrogated glycogen synthase kinase 3beta (GSK3beta)-mediated degra

172 1 interacts with Nrf2 and stabilizes it from glycogen synthase kinase 3beta (GSK3beta)-mediated phosp

173 FN signaling pathways occurs at the point of glycogen synthase kinase 3beta (GSK3beta)-TANK-binding k

174 t VRK2 activity was negatively controlled by glycogen synthase kinase 3beta (GSK3beta).

175 g protein binding protein kinase A (PKA) and glycogen synthase kinase 3beta (GSK3beta).

176 These include protein kinase A (PKA) and glycogen synthase kinase 3beta (GSK3beta).

177 ivation and this occurs in part by targeting glycogen synthase kinase 3beta (GSK3beta).

178 inhibition of the tumor suppressors PTEN and glycogen synthase kinase 3beta (GSK3beta).

179 n (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3beta (GSK3beta).

180 at S199 (hTau-S199-P) by the protein kinase glycogen synthase kinase 3beta (GSK3beta).

181 atty acids, and this suppression depended on glycogen synthase kinase 3beta activation and induction

182 au phosphorylation and solubility, increased glycogen synthase kinase 3beta activity, compromised lon

183 protein that plays a key role in attenuating glycogen synthase kinase 3beta activity, leading to aber

184 2A and recruits protein phosphatase 2A with glycogen synthase kinase 3beta and beta-catenin, inducin

185 Glycogen synthase kinase 3beta and Foxo1 are two PI-3K-r

186 isms involved demonstrate that ASPH binds to glycogen synthase kinase 3beta and inhibits its subseque

187 ibition of ASPH activity, phosphorylation of glycogen synthase kinase 3beta and p16 expression were i

188 reasing Ser9 phosphorylation-inactivation of glycogen synthase kinase 3beta by RBMY, thereby impeding

189 ted with release of the inhibitory effect of glycogen synthase kinase 3beta function by decreasing Se

190 in, and that beta-catenin activation through glycogen synthase kinase 3beta inhibition leads to FANCC

191 ment, and reduced Akt (protein kinase B) and glycogen synthase kinase 3beta phosphorylation.

192 al nuclear factor kappaB pathway and the Akt-glycogen synthase kinase 3beta signaling axis, respectiv

193 bound IRF1 turnover is promoted by GSK3beta (Glycogen Synthase Kinase 3beta) via phosphorylation of t

194 t3a (the canonical activator), inhibitors of glycogen synthase kinase 3beta, and small-interfering RN

195 cocorticoid kinase 1 (SGK1), an inhibitor of glycogen synthase kinase 3beta, as part of this pathway.

196 ced tumor growth, induced phosphorylation of glycogen synthase kinase 3beta, enhanced p16 expression

197 n showed AQP1 interaction with beta-catenin, glycogen synthase kinase 3beta, LRP6, and Axin1.

198 of cyclin-dependent protein kinase 5 (Cdk5), glycogen synthase kinase 3beta, protein phosphatase 1, o

199 e kinase 3beta by RBMY, thereby impeding the glycogen synthase kinase 3beta-dependent degradation of

200 Molecularly, ROCK inhibition induced glycogen synthase kinase 3beta-dependent phosphorylation

201 ta-catenin expression and stabilization in a glycogen synthase kinase 3beta-independent manner.

202 signal-regulated protein kinase modules and glycogen synthase kinase 3beta.

203 ead box protein O1 transcription factors and glycogen synthase kinase 3beta.

204 7, p38 mitogen-activated protein kinase, and glycogen synthase kinase 3beta.

205 Additionally, in the current study, glycogen synthase kinase appears to attenuate tau pathol

206 In both cell types, insulin blocks glycogen synthase kinase beta (GSK3beta) activity.

207 Here we show that the glycogen synthase kinase beta (GSK3beta) expression is e

208 In a previous study, the FGK3 glycogen synthase kinase gene orthologous to mammalian G

209 A point mutation in a putative glycogen synthase kinase phosophorylation site within th

210 lates alcohol-induced BK internalization via glycogen synthase kinase phosphorylation.

211 f lithium, in which fine-tuned regulation of glycogen synthase kinase type 3, a prime target for lith

212 sly showed that the serine/threonine kinase, glycogen synthase kinase, GSK-3alpha/beta, is a central

213 The challenge for glycogen synthase kinase-3 (GSK-3) inhibitor design lies

214 plex 1 (mTORC1) inhibitor rapamycin, and the glycogen synthase kinase-3 (GSK-3) inhibitor lithium act

215 Combining glycogen synthase kinase-3 (GSK-3) inhibitors with VPA o

216 Activation of glycogen synthase kinase-3 (GSK-3) interferes with micro

217 Glycogen synthase kinase-3 (GSK-3) is a constitutively a

218 Glycogen synthase kinase-3 (Gsk-3) is a key regulator of

219 Glycogen synthase kinase-3 (GSK-3) is a key regulator of

220 Glycogen synthase kinase-3 (GSK-3) is one of the few sig

221 bition of the histone deacetylase (HDAC) and glycogen synthase kinase-3 (GSK-3) pathways, which cause

222 Glycogen synthase kinase-3 (GSK-3) regulates multiple ce

223 de et al. uses phosphoproteomics to identify glycogen synthase kinase-3 (GSK-3) substrates in mouse e

224 Predictably, inhibition of glycogen synthase kinase-3 (GSK-3), which results from a

225 nt oxazole-4-carboxamide-based inhibitors of glycogen synthase kinase-3 (GSK-3).

226 ling events that result in the inhibition of glycogen synthase kinase-3 (GSK-3)beta represent an adap

227 ositol-3 kinase/Akt (IRS-PI3K-Akt) pathways, glycogen synthase kinase-3 (GSK3) and mammalian target o

228 T3 signaling, and simultaneous inhibition of glycogen synthase kinase-3 (GSK3) and MAP kinase/ERK kin

229 Glycogen synthase kinase-3 (GSK3) are ubiquitously expre

230 haracterize a novel activation mechanism for glycogen synthase kinase-3 (GSK3) by the sphingolipids p

231 The glycogen synthase kinase-3 (GSK3) family kinases are cen

232 Treatment with lithium or a glycogen synthase kinase-3 (GSK3) inhibitor corrects beh

233 ia containing fetal bovine serum (FBS) and a glycogen synthase kinase-3 (GSK3) inhibitor, and in seru

234 e describe a cell-engineering strategy using glycogen synthase kinase-3 (GSK3) inhibitor-loaded nanop

235 Here, we report that glycogen synthase kinase-3 (GSK3) is a critical determin

236 Glycogen synthase kinase-3 (GSK3) is an important signal

237 Hippocampal glycogen synthase kinase-3 (GSK3) is hyperactive in the

238 We found that glycogen synthase kinase-3 (GSK3) is overactivated in co

239 Moreover, induction of glycogen synthase kinase-3 (GSK3) performed using a Wnt

240 Glycogen synthase kinase-3 (GSK3) regulates many physiol

241 Glycogen synthase kinase-3 (GSK3) was found to be an ups

242 lian target of rapamycin signaling, glucose, glycogen synthase kinase-3 and liver kinase B1, protein

243 Next, we apply this strategy to study glycogen synthase kinase-3 beta (GSK-3beta), a kinase ab

244 Glycogen synthase kinase-3 beta (GSK-3beta), a serine/th

245 drogenase kinase-1, or its downstream target glycogen synthase kinase-3 did not prevent CCR9 expressi

246 enhanced risk for SZ and/or BD can activate glycogen synthase kinase-3 isozymes (GSK3alpha and beta)

247 Pharmacological inhibition of glycogen synthase kinase-3 was sufficient to reverse the

248 , while application of Bikinin (inhibitor of glycogen synthase kinase-3), which activated BR signalin

249 to ERK1/2 and Akt, including p70 S6-kinase, glycogen synthase kinase-3, ribosomal S6 kinase, c-Jun,

250 hium chloride, a reversible inhibitor of the glycogen synthase kinase-3, that rescued NMJ defects in

251 lation primes for Ser-159 phosphorylation by glycogen synthase kinase-3.

252 m of this study was to determine the role of glycogen synthase kinase-3alpha (GSK-3alpha) in post-MI

253 rexpression of TDP-43 leads to activation of glycogen synthase kinase-3beta (GSK-3beta) and that GSK-

254 dated AD targets beta-secretase (BACE-1) and glycogen synthase kinase-3beta (GSK-3beta) by attacking

255 PSC-CMs in vitro (i.e., 100- to 250-fold) by glycogen synthase kinase-3beta (GSK-3beta) inhibition us

256 Herein we report that glycogen synthase kinase-3beta (GSK-3beta) is phosphoryl

257 sis coli tumor suppressor protein (APC), and glycogen synthase kinase-3beta (GSK-3beta), which could

258 atocytes, which led to a delayed increase in glycogen synthase kinase-3beta (GSK-3beta)-mediated hepa

259 demonstrate that alcohol intake also blocks glycogen synthase kinase-3beta (GSK-3beta)-phosphorylati

260 hase and the phosphorylation (inhibition) of glycogen synthase kinase-3beta (GSK-3beta).

261 ein function are via a pathway that involves glycogen synthase kinase-3beta (GSK-3beta).

262 Glycogen synthase kinase-3beta (GSK3beta) activity is in

263 nted pre-synaptic protein deficit, decreased glycogen synthase kinase-3beta (GSK3beta) activity, and

264 finding is the pronounced downregulation of glycogen synthase kinase-3beta (Gsk3beta) and upregulati

265 Glycogen synthase kinase-3beta (GSK3beta) controls many

266 Glycogen synthase kinase-3beta (GSK3beta) has diverse bi

267 Here we demonstrate that hyperactivity of glycogen synthase kinase-3beta (GSK3beta) in the atrium

268 Glycogen synthase kinase-3beta (GSK3beta) plays a critic

269 uclear Nrf2 export/degradation machinery via glycogen synthase kinase-3beta (Gsk3beta) signaling was

270 lted in increased phosphorylation of Akt and glycogen synthase kinase-3beta (GSK3beta), leading to en

271 tion and insulin secretion via regulation of glycogen synthase kinase-3beta (GSK3beta).

272 ith emerin and beta-actin, and activation of glycogen synthase kinase-3beta (GSK3beta).

273 s (ankyrin G, EB1) were knocked down or when glycogen synthase kinase-3beta (GSK3beta; an AD-associat

274 panied by hyperphosphorylation of substrates glycogen synthase kinase-3beta and mammalian target of r

275 hase survival pathway, and the inhibition of glycogen synthase kinase-3beta and nuclear factor kappa

276 Such glycogen synthase kinase-3beta inactivation causes chang

277 erentiated hPSCs into mesoderm cells using a glycogen synthase kinase-3beta inhibitor for 3 days, the

278 mbinant Wnt3a protein or CHIR-99021 (CHIR, a glycogen synthase kinase-3beta inhibitor) caused a dose-

279 ha/wrd pathway in the motoneuron antagonizes glycogen synthase kinase-3beta kinase activity to preven

280 on of GABAergic transmission via D2 receptor-glycogen synthase kinase-3beta signaling dramatically re

281 The phosphorylation and inactivation of glycogen synthase kinase-3beta was dependent on mammalia

282 GSK-3beta (glycogen synthase kinase-3beta) is highly associated wit

283 l as by inhibition of the Akt-GSK-3beta (Akt-glycogen synthase kinase-3beta) pathway.

284 orylation of the inhibitory Ser-9 residue of glycogen synthase kinase-3beta, a primary Tau kinase inv

285 ollowed by phosphorylation (inactivation) of glycogen synthase kinase-3beta, at least in part via STA

286 cyclin D1, E-cadherin, beta-catenin, Dvl-1, glycogen synthase kinase-3beta, axin-1, and adenomatous

287 no changes in Ctnnb1 expression, activity of glycogen synthase kinase-3beta, known to phosphorylate a

288 activator of beta-catenin via inhibition of glycogen synthase kinase-3beta, reversed the inhibition

289 d to the phosphorylation and inactivation of glycogen synthase kinase-3beta, which resulted in inhibi

290 inding (CREB) protein levels to decreaseviaa glycogen synthase kinase-3beta-dependent mechanism.

291 ial-mesenchymal transition by repressing AKT/glycogen synthase kinase-3beta/beta-catenin signaling.

292 Recent evidence suggests that glycogen-synthase kinase 3beta (GSK3beta) plays a key ro

293 nalling proteins, protein kinase B (Akt) and glycogen synthase-kinase 3beta, in maternal liver (P < 0

294 ological or genetic inhibition of tau kinase glycogen-synthase-kinase-3beta (GSK-3beta).

295 ntify the Arabidopsis (Arabidopsis thaliana) GLYCOGEN SYNTHASE KINASE3 (GSK3)/Shaggy-like kinase ASKa

296 nt link between phosphoinositol-3-kinase and glycogen synthase kinase3 and demonstrates the potential

297 athway has many downstream targets including glycogen synthase kinase3 which is a major regulatory ki

298 b The Ppp1r3b deletion significantly reduced glycogen synthase protein abundance, and the remaining p

299 of glycogenin-1 or impaired interaction with glycogen synthase underlies this new form of glycogen st

300 50% lower, and the amount of phosphorylated glycogen synthase was 34% lower, indicating activation o